Edgar Lomax CO Abb Vie Inc. Transaction History

Edgar Lomax CO

$1.63 Billion
Q3 2024

A detailed history of Edgar Lomax CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Edgar Lomax CO holds 65,853 shares of ABBV stock, worth $11.7 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares

65,853

Previous 66,878 1.53%

Holding current value

$11.7 Million

Previous $11.5 Million 13.37%

% of portfolio

0.8%

Previous 0.75%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $167,936 - $204,313	-1,025 Reduced 1.53%	65,853 $13 Million
Q2 2024 Aug 13, 2024	SELL	$154.79 - $180.76 $126,927 - $148,223	-820 Reduced 1.21%	66,878 $11.5 Million
Q1 2024 May 13, 2024	BUY	$159.82 - $182.1 $2.59 Million - $2.95 Million	16,194 Added 31.44%	67,698 $12.3 Million
Q4 2023 Feb 09, 2024	SELL	$137.6 - $154.97 $282,080 - $317,688	-2,050 Reduced 3.83%	51,504 $7.98 Million
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $130,250 - $150,783	-975 Reduced 1.79%	53,554 $7.98 Million
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $97,924 - $121,861	-739 Reduced 1.34%	54,529 $7.35 Million
Q1 2023 May 12, 2023	SELL	$144.61 - $166.54 $2.05 Million - $2.37 Million	-14,210 Reduced 20.45%	55,268 $8.81 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $51,174 - $61,371	-370 Reduced 0.53%	69,478 $11.2 Million
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $53,684 - $61,572	-400 Reduced 0.57%	69,848 $9.37 Million
Q2 2022 Aug 10, 2022	BUY	$137.62 - $174.96 $272,487 - $346,420	1,980 Added 2.9%	70,248 $10.8 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $27.6 Million - $34.2 Million	-209,085 Reduced 75.39%	68,268 $11.1 Million
Q4 2021 Feb 11, 2022	SELL	$107.43 - $135.93 $298,118 - $377,205	-2,775 Reduced 0.99%	277,353 $37.6 Million
Q3 2021 Nov 12, 2021	SELL	$106.4 - $120.78 $375,592 - $426,353	-3,530 Reduced 1.24%	280,128 $30.2 Million
Q2 2021 Aug 09, 2021	SELL	$105.21 - $117.21 $712,797 - $794,097	-6,775 Reduced 2.33%	283,658 $32 Million
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $17.1 Million - $18.8 Million	166,690 Added 134.71%	290,433 $31.4 Million
Q4 2020 Feb 11, 2021	SELL	$80.49 - $108.67 $177,078 - $239,074	-2,200 Reduced 1.75%	123,743 $13.3 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $438,141 - $514,233	5,100 Added 4.22%	125,943 $11 Million
Q2 2020 Aug 12, 2020	BUY	$73.37 - $98.18 $183,425 - $245,450	2,500 Added 2.11%	120,843 $11.9 Million
Q1 2020 May 14, 2020	SELL	$64.5 - $97.79 $11.8 Million - $17.8 Million	-182,400 Reduced 60.65%	118,343 $9.02 Million
Q4 2019 Feb 11, 2020	SELL	$72.13 - $90.25 $540,975 - $676,875	-7,500 Reduced 2.43%	300,743 $26.6 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $207,834 - $249,876	-3,300 Reduced 1.06%	308,243 $23.3 Million
Q2 2019 Aug 09, 2019	SELL	$65.7 - $83.98 $308,790 - $394,706	-4,700 Reduced 1.49%	311,543 $22.7 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $8.55 Million - $10.1 Million	110,775 Added 53.91%	316,243 $25.5 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $233,549 - $288,030	-3,000 Reduced 1.44%	205,468 $18.9 Million
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $666,825 - $741,300	-7,500 Reduced 3.47%	208,468 $19.7 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $136,914 - $162,000	1,525 Added 0.71%	215,968 $20 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $7.83 Million - $10.5 Million	85,125 Added 65.83%	214,443 $20.3 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $359,583 - $394,313	-4,015 Reduced 3.01%	129,318 $12.5 Million
Q3 2017 Nov 13, 2017	BUY	$69.85 - $89.22 $9.31 Million - $11.9 Million	133,333	133,333 $11.8 Million

Others Institutions Holding ABBV

# of Institutions

3,848

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $313B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgar Lomax CO, based on Form 13F filings with the SEC.

News

Stay updated on Edgar Lomax CO with notifications on news.

Account